Loading organizations...
SJG Group, operating as S. J. & G. Fazul Ellahie (Pvt.) Ltd., develops and manufactures healthcare solutions, specializing in quality pharmaceuticals. The company utilizes robust research and development alongside stringent quality controls, ensuring product safety and efficacy. Their approach emphasizes innovation, delivering pharmaceutical offerings through efficient supply chain management.
Established in 1889, the company began as S. J. & G. Fazul Ellahie (Pvt.) Ltd., pioneering pharmaceutical excellence. The initial insight stemmed from a commitment to advancing healthcare through reliable, effective medicinal solutions. This legacy has positioned SJG Group as a long-standing industry leader, consistently driven by a vision to improve global public health since its inception.
SJG Group’s pharmaceuticals serve a global customer base, enhancing health and well-being worldwide. The company contributes to a healthier planet through sustainable practices and responsible sourcing. Their forward-looking vision centers on building a resilient, sustainable business, consistently delivering exceptional healthcare solutions across diverse international markets.
SJG Partners has 1 tracked investment across 1 company. The latest tracked deal is $15.3M Series C in Sky Labs in October 2023.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Oct 17, 2023 | Sky Labs | $15.3M Series C | — | DEV Sisters Ventures, K2 Investment Partners, Korea Development Bank, Openwater Investment |